Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6521 | 1406 | 34.9 | 71% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | INJECTING DRUG USE | Author keyword | 20 | 20% | 7% | 93 |
2 | HEPATITIS C TREATMENT | Author keyword | 11 | 45% | 1% | 18 |
3 | VIRAL HEPATITIS CLIN PROGRAM | Address | 9 | 47% | 1% | 14 |
4 | EDMOND DE ROTH ILD FDN CHEM DEPENDENCY | Address | 8 | 75% | 0% | 6 |
5 | PEOPLE WHO INJECT DRUGS | Author keyword | 8 | 26% | 2% | 27 |
6 | DRUG TREATMENT PROGRAMS | Author keyword | 7 | 53% | 1% | 9 |
7 | PL SOCIAL HLTH | Address | 6 | 44% | 1% | 11 |
8 | HIV SOCIAL | Address | 5 | 11% | 3% | 44 |
9 | INJECTING DRUG USERS | Author keyword | 5 | 12% | 3% | 39 |
10 | DRUGS HLTH BEHAV | Address | 5 | 15% | 2% | 30 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | OPIATE SUBSTITUTION THERAPY | 21 | 75% | 1% | 15 |
2 | INNER CITY RESIDENTS | 8 | 75% | 0% | 6 |
3 | ANTIVIRAL TREATMENT | 8 | 17% | 3% | 43 |
4 | PREPARATION EQUIPMENT | 5 | 54% | 0% | 7 |
5 | HUMAN IMMUNODEFICIENCY | 5 | 11% | 3% | 41 |
6 | PARAPHERNALIA | 4 | 47% | 0% | 7 |
7 | HCV SERVICES | 4 | 75% | 0% | 3 |
8 | SYRINGE PROGRAMS | 4 | 40% | 1% | 8 |
9 | ABUSE TREATMENT UNITS | 4 | 56% | 0% | 5 |
10 | GLOBAL EPIDEMIOLOGY | 4 | 12% | 2% | 30 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review | 2015 | 1 | 71 | 59% |
Barriers to hepatitis C treatment | 2012 | 33 | 47 | 72% |
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence | 2009 | 90 | 66 | 62% |
Underascertainment of Acute Hepatitis C Virus Infections in the US Surveillance System | 2015 | 1 | 18 | 50% |
Epidemiology and natural history of HCV infection | 2013 | 82 | 129 | 22% |
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention | 2014 | 8 | 168 | 57% |
A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs | 2011 | 69 | 51 | 59% |
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs | 2015 | 1 | 83 | 33% |
Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment | 2012 | 19 | 34 | 71% |
Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers | 2012 | 17 | 76 | 76% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | VIRAL HEPATITIS CLIN PROGRAM | 9 | 47% | 1.0% | 14 |
2 | EDMOND DE ROTH ILD FDN CHEM DEPENDENCY | 8 | 75% | 0.4% | 6 |
3 | PL SOCIAL HLTH | 6 | 44% | 0.8% | 11 |
4 | HIV SOCIAL | 5 | 11% | 3.1% | 44 |
5 | DRUGS HLTH BEHAV | 5 | 15% | 2.1% | 30 |
6 | EXCELLENCE INJECTING DRUG USE | 4 | 67% | 0.3% | 4 |
7 | PENDER COMMUNITY HLTH | 4 | 67% | 0.3% | 4 |
8 | BLOOD BORNE VIRUSES SEXUALLY TRANSMITTED INFECT | 3 | 100% | 0.2% | 3 |
9 | ORG ACHIEVE SOLUT SUBSTANCE ABUSE | 3 | 100% | 0.2% | 3 |
10 | BIOSTAT DATABASES PROGRAM | 3 | 40% | 0.4% | 6 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000205131 | ACUTE HEPATITIS C//INTRAFAMILIAL TRANSMISSION//MOTHER TO INFANT TRANSMISSION |
2 | 0.0000200783 | REPRINT SERV//HEPATITIS VACCINATION//EDMOND DE ROTH ILD FDN |
3 | 0.0000189027 | JENS//BEHAV HLTH CLIN NEUROSCI//NW HEPATITIS OURCE C |
4 | 0.0000182514 | INJECTION DRUG USERS//INJECTING DRUG USE//SYRINGE EXCHANGE |
5 | 0.0000156919 | TELAPREVIR//RIBAVIRIN//BOCEPREVIR |
6 | 0.0000122284 | HIV HCV CO INFECTION//HIV HCV COINFECTION//COINFECTION |
7 | 0.0000112624 | CHIRURG D//ALCOHOLIC LIVER DISEASE ALD//CHRONIC HEPATITIS INDUCED BY ALCOHOL |
8 | 0.0000099911 | PRISONS//PRISONERS//PRISON |
9 | 0.0000085395 | GROIN INJECTING//INTRAARTERIAL INJECTION//INTRA ARTERIAL INJECTION |
10 | 0.0000071651 | HCV GENOTYPES//INTERFERON SENSITIVITY DETERMINING REGION//HYPERVARIABLE REGION 1 |